Saeedeh Talebi

Dr. Saeedeh Talebi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
STSaeedeh Talebi
Saeedeh Talebi
HKHamid Reza Kianifar
Hamid Reza Kianifar
AMAtieh Mehdizadeh
Atieh Mehdizadeh

19 November 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
PAParastoo Asghari
Parastoo Asghari
MAMaryam Ahmadi-Khorram
Maryam Ahmadi-Khorram
AHAlireza Hatami
Alireza Hatami
STSaeedeh Talebi
Saeedeh Talebi
AAAsma Afshari
Asma Afshari
Background: Non-alcoholic fatty liver disease (NAFLD) affects nearly one-third of the adult population worldwide, and currently, there are no approved pharmacological therapies. Akkermansia muciniphila, a bacterium found in the gut, has been identified as a promising therapeutic candidate due to its influence on the gut-liver axis. Objective: This systematic review aims to evaluate the efficacy of A. muciniphila in preclinical mouse models of NAFLD, focusing on its effects on body weight, glucolipid metabolism, liver function, gut barrier integrity, gut microbiota composition, inflammation, and immune response. Methods: Following PRISMA 2020 guidelines, a comprehensive search was conducted in PubMed, Scopus, Web of Science, and Google Scholar until September 30, 2025, for studies investigating A. muciniphila interventions in NAFLD mouse models. Inclusion criteria comprised mouse models of NAFLD, MAFLD, or NASH that involved A. muciniphila administration alongside a control group. Data were extracted concerning study characteristics, intervention details, and outcomes. The quality assessment of the studies was performed using the SYRCLE’s Risk of Bias tool. Results: Thirteen studies were included, predominantly employing C57BL/6 mice and high-fat diets. Results indicated that A. muciniphila reduced body weight, hepatic steatosis, and serum lipid levels, while improving insulin sensitivity and decreasing liver enzyme levels (ALT, AST). It also enhanced gut barrier function by upregulating tight junction protein expression and reducing lipopolysaccharide (LPS) translocation. Furthermore, anti-inflammatory effects were evidenced by decreased levels of TNF-α, IL-6, and MCP-1, alongside immunomodulation through the balance of Th17 and Treg cells. Conclusion: A. muciniphila exhibits potential in the management of preclinical NAFLD by improving metabolic, hepatic, and gut-related parameters. However, the absence of clinical trials limits the translatability of these findings. Future clinical investigations are imperative to establish efficacy, optimize dosing, and evaluate long-term safety. Trial registration: This systematic review has been documented with PROSPERO under the identifier: CRD42024610627. Graphical

19 October 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
STSaeedeh Talebi
Saeedeh Talebi
PEPeyman Eshraghi
Peyman Eshraghi

1 January 2022 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
STSaeedeh Talebi
Saeedeh Talebi
Andrew DayAndrew Day
Andrew Day
MKMajid Khadem-Rezaiyan
Majid Khadem-Rezaiyan
GRGolnaz Ranjbar
Golnaz Ranjbar
MZMitra Zarei
Mitra Zarei
HKHamid Reza Kianifar
Hamid Reza Kianifar
Talebi S, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Jan;25(1):1-12. https://doi.org/10.5223/pghn.2022.25.1.1

21 December 2025 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
ENElyas Nattagh-Eshtivani
Elyas Nattagh-Eshtivani
HBHanieh Barghchi
Hanieh Barghchi
AMAmir Hossein Mansouri
Amir Hossein Mansouri
PRPegah Rahbarinejd
Pegah Rahbarinejd
AMAmin Mokari-Yamchi
Amin Mokari-Yamchi
NPNaseh Pahlavani
Naseh Pahlavani
Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are chronic conditions characterized by rel